These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32518611)

  • 1. Adherence to National Comprehensive Cancer Network Guidelines for
    Bobbili P; Olufade T; DerSarkissian M; Shenolikar R; Yu H; Duh MS; Tung N
    Hered Cancer Clin Pract; 2020; 18():13. PubMed ID: 32518611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.
    Beck AC; Yuan H; Liao J; Imperiale P; Shipley K; Erdahl LM; Sugg SL; Weigel RJ; Lizarraga IM
    Am J Surg; 2020 Jan; 219(1):145-149. PubMed ID: 31255259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
    Lee SS; Rajeev P; Finning S; Oh C; Pothuri B
    Gynecol Oncol; 2023 Mar; 170():32-37. PubMed ID: 36610379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
    Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K
    Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
    Chun DS; Berse B; Venne VL; DuVall SL; Filipski KK; Kelley MJ; Meyer LJ; Icardi MS; Lynch JA
    Fam Cancer; 2017 Jan; 16(1):41-49. PubMed ID: 27589855
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
    J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
    Barcenas CH; Shafaee MN; Sinha AK; Raghavendra A; Saigal B; Murthy RK; Woodson AH; Arun B
    J Natl Compr Canc Netw; 2018 May; 16(5):518-524. PubMed ID: 29752326
    [No Abstract]   [Full Text] [Related]  

  • 8. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
    Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
    Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
    Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
    JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of
    Forbes C; Fayter D; de Kock S; Quek RG
    Cancer Manag Res; 2019; 11():2321-2337. PubMed ID: 30962720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based Practice.
    Mendenhall MA; Guinigundo A; Davies D; Ward P; Drosick DR; Waterhouse DM
    JCO Oncol Pract; 2024 Feb; 20(2):262-267. PubMed ID: 37369093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of Universal
    Emborgo TS; Saporito D; Muse KI; Barrera AMG; Litton JK; Lu KH; Arun BK
    JNCI Cancer Spectr; 2020 Apr; 4(2):pkaa002. PubMed ID: 32211581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
    JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.
    Abdel-Razeq H; Tamimi F; Abujamous L; Abdel-Razeq R; Abunasser M; Edaily S; Abdulelah H; Khashabeh RA; Bater R
    Front Oncol; 2022; 12():673094. PubMed ID: 35402282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.
    Toss A; Molinaro E; Venturelli M; Domati F; Marcheselli L; Piana S; Barbieri E; Grandi G; Piombino C; Marchi I; Tenedini E; Tagliafico E; Tazzioli G; Cortesi L
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of early-stage breast cancer patients that meet indications for
    Xiang H; Xin L; Liu Q; Zhang H; Zhang S; Ye J; Cheng Y; Li T; Liu Y; Xu L
    Chin J Cancer Res; 2020 Apr; 32(2):163-174. PubMed ID: 32410794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic Barriers for Genetic Testing in High-Risk Breast Cancer Patients in the Northern Michigan Area.
    Hebert D; Pacheco F; WintonLi L; Taj A
    Cureus; 2022 Mar; 14(3):e22966. PubMed ID: 35411261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
    Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
    Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.